CIVIL-SOCIETY-20
22.3.2020 18:51:13 CET | Business Wire | Press release
The following is a statement by Civil 20:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200322005022/en/
The events of this year alone, starting with the bushfires in Australia and moving to the outbreak of COVID-19, underscored the ever-growing complexity of our global shared challenges and expose the weaknesses of the current dominant economic system, and how it deepens inequalities between individuals and countries. We ask that G20 leaders recognize our new global reality and reorient this year’s G20 priorities towards building a more resilient global governance.
G20 leaders need to uphold the principles of human rights, civic engagement, and democracy. As the crisis develops, the C20 observes with great alarm the continued deterioration of the situation for many vulnerable groups in different societies. Governments must protect and extend medical care to all people without leaving anyone behind.
The infodemic surrounding the disease is equally fatal to the virus. The C20 stands in solidarity with communities suffering as a result of different governments’ lack of transparency. Governments are accountable in their response to the crisis, and work on empowering local communities and civil society actors in responding to the outbreak.
We can learn from previous public health emergencies the importance of quality care continuum, protection of human rights, anti-discrimination and isolation of people living with the diseases and affected communities. COVID-19 is a sobering reminder that we need to increase investment in what we know works: strong international partnerships, building health care delivery systems that reach everyone, research and development, and an approach to care that prioritizes the most marginalized. The C20 urges that G20 leaders consider the recommendations in the statement on pandemic preparedness released jointly with the Business 20, Labor 20, Think 20, Women 20 and Youth 20.
Another emerging lesson out of this emergency, is that hyper-globalization of our supply chains is making our trade systems extremely vulnerable to shocks. The C20 cautions G20 leaders against the ongoing attempts in trade agreement negotiations to open “health markets” to foreign investors and competition, turning health systems into yet another investment opportunity. We worry that the divide between those who can afford healthcare and those who cannot will be exacerbated.
The C20 warns that inequalities will ensue as a consequence of the outbreak. Labor policies need to be put in place to address the needs of the most vulnerable, who cannot afford to sit at home, and prepare for the expected rise in working poverty, especially in countries with a high informal economy, where women are over-represented.
The world is in need of multilateral coordination of an effective response to the economic crisis that provides adequate fiscal and monetary stimulus, while safeguarding liquidity from misuse by speculative activities. A fairly designed stimulus package should take into account not only the interest of businesses and SMEs, but also households, workers, and the most vulnerable.
A problem with multiple dimensions requires a solution by multiple actors. Members of Civil Society and humanitarian NGOs continue to face tightened financial restrictions due to risk and cost aversion by banks in complying with FATF regulations. Such financial exclusion limits our ability to respond to global emergencies.
We implore the G20 Leaders to take immediate action in responding to the substantial impact on education and the dwindling prospects of ensuring access. The world is entirely unequipped to maintain a promise of “education for all”; particularly in contexts where classrooms can no longer provide a safe environment for learning.
The C20 calls on G20 leaders to expand this year’s G20 priorities to vigilantly respond to the changes in the labor market through expanding social protection systems, ensure digital and eLearning is accessible across, prioritize child online safety, address rising risks to debt sustainability in emerging markets as they face urgent financing needs to improve health systems capacity to respond to the COVID-19 outbreak, including debt relief and attending to their exposure to volatile capital flows.
Civil Society 20 (C20) is one of the eight official Engagement Groups of the G20. It provides a platform of Civil Society Organizations around the world to bring forth a non-government and non-business voice.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20200322005022/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Brenus Pharma Announces FDA Acceptance of IND Application for STC-1010 (BreAK-CRC001) in MSS Metastatic Colorectal Cancer (mCRC)27.5.2026 08:49:00 CEST | Press release
STC-1010 is a first-in-class allogeneic in vivo immunotherapy for which the FDA has authorized clinical evaluation in the U.S. under the BreAK-CRC001 study. This strategic milestone enables the company to execute a global clinical strategy following European regulatory approvals (ANSM, AFMPS), first patients dosed with preliminary results and good tolerability observed in early Phase Ia. First data are expected to be presented during ESMO annual congress 2026. Brenus Pharma, a clinical stage biotechnology company developing novel in vivo immunotherapies for solid tumors, announced that the U.S. Food and Drug Administration (FDA) has accept the company's Investigational New Drug (IND) application for its first drug candidate, STC-1010, in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). STC-1010 is designed to address a critical unmet need worldwide. Approximately 95% of mCRC patients have MSS tumors, which demonstrate minimal response to standard immunotherapies. The FD
Tide Crosses 2 Million Members Worldwide - Big Step Forward in Mission to Support and Grow Small Businesses27.5.2026 08:00:00 CEST | Press release
Continuing to grow in the UK and internationally, with India seeing especially strong member growth in the last 12 months In the UK, Tide has 15% market share and has helped small businesses access over £1.75bn in credit Rapid roll out of products; from admin, accounting and tax tools; subscription options; payment solutions; government registrations; bill payments and credit Tide, the UK’s leading business management platform, today announces it has crossed 2 million members globally, with India in particular seeing strong growth. More than 1.1 million small businesses joined Tide in India since the company launched there in December 2022. This makes India Tide’s fastest-growing market by member acquisition. The UK is Tide’s home market, with 900,000 SMEs, 15% market share, and the majority of the company’s revenue. Tide’s steadily expanding its presence in Europe, with Germany and France, where the platform is gaining strong traction, thanks to millions of small businesses turning to
Alfasigma presents first data on filgotinib from the Phase 3 OLINGUITO trial in axial spondyloarthritis at EULAR 202627.5.2026 08:00:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific and investor media only.In the OLINGUITO Phase 3 study in radiographic (r) and non-radiographic (nr) axial spondyloarthritis (axSpA) a significantly greater proportion of patients achieved the prespecified primary endpoint of ASAS40 with filgotinib compared with placebo at week 16.The improvements in signs and symptoms of axSpA with filgotinib, an oral, once-daily JAK1 preferential inhibitor, were observed as early as week 1 and maintained over 52 weeks of treatment.In the r-axSpA and nr-axSpA filgotinib groups, of those achieving a response in the prespecified primary endpoint of ASAS40 at week 16, 84.6% and 78.0% maintained their responses to week 52, respectively.In OLINGUITO no new safety signals were observedfor filgotinib over 52 weeks, and the safety profile was consistent with the known overall safety profile.Primary results from the Phase 3 OLINGUITO tria
Royal London Asset Management Expands Relationship with SS&C to Service New Australian Funds27.5.2026 00:00:00 CEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that Royal London Asset Management, a leading U.K. fund management company, has extended its relationship with SS&C. SS&C Global Investor & Distribution Solutions will provide fund administration and unit registry services for its new range of Australian active funds, including: Royal London Global Equity Diversified Fund Royal London Global Equity Enhanced Fund Royal London Global Equity Select Fund Royal London Short Duration Global High Yield Bond Fund RLAM is part of Royal London, the U.K.’s largest mutual life, pensions and investment company. SS&C services approximately £72bn in assets under management across its U.K. fund range. Equity Trustees will serve as the Responsible Entity for RLAM’s new funds, which have launched with around AUD $1 billion in AUM. The unit trusts are structured as feeder funds, providing investors with indirect exposure to RLAM’s range of Dublin-domiciled Undertakings for Collective Investm
SLB Announces Date for Second-Quarter 2026 Results Conference Call26.5.2026 19:00:00 CEST | Press release
SLB (NYSE: SLB) will hold a conference call on July 24, 2026, to discuss the results for the second quarter ending June 30, 2026. The conference call is scheduled to begin at 9:30 a.m. U.S. Eastern time and a press release regarding the results will be issued at 7:00 a.m. U.S. Eastern time. To access the conference call, listeners should contact the Conference Call Operator at +1 (800) 715-9871 within North America or +1 (646) 307-1963 outside of North America approximately 10 minutes prior to the start of the call and the access code is 3440360. A webcast of the conference call will be broadcast simultaneously at https://events.q4inc.com/attendee/157027565 on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call, a replay will be available at www.slb.com/irwebcast until July 31, 2026, and can be accessed by dialing +1 (800) 770-2030 within North America or +1
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
